Switch theme
Sign up to access all valuation multiples
Goodwill Pharma Nyrt is a full service pharma partner for the CEE region. The company s core activities include pharmaceutical logistics and distribution, pharmaceutical registration, full pharmaceutical marketing services, medical promotion, manufacturer and brand representation, own-licensed product development, manufacturing and marketing of proprietary pharmaceuticals and dietary supplements.
n/a
Last FY Revenue $26K
Last FY EBITDA $4K
$56.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Goodwill Pharma achieved revenue of $26K and an EBITDA of $4K.
Goodwill Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Goodwill Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $26K | XXX | XXX | XXX |
| Gross Profit | XXX | $9K | XXX | XXX | XXX |
| Gross Margin | XXX | 34% | XXX | XXX | XXX |
| EBITDA | XXX | $4K | XXX | XXX | XXX |
| EBITDA Margin | XXX | 16% | XXX | XXX | XXX |
| EBIT | XXX | $2K | XXX | XXX | XXX |
| EBIT Margin | XXX | 9% | XXX | XXX | XXX |
| Net Profit | XXX | $2K | XXX | XXX | XXX |
| Net Margin | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | $3K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Goodwill Pharma's stock price is HUF 190 (or $1).
Goodwill Pharma has current market cap of HUF 20.4B (or $56.7M), and EV of HUF 20.4B (or $56.8M).
See Goodwill Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $56.8M | $56.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Goodwill Pharma has market cap of $56.7M and EV of $56.8M.
Goodwill Pharma's trades at 2190.2x EV/Revenue multiple, and 13990.3x EV/EBITDA.
Equity research analysts estimate Goodwill Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Goodwill Pharma's P/E ratio is not available.
See valuation multiples for Goodwill Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $56.7M | XXX | $56.7M | XXX | XXX | XXX |
| EV (current) | $56.8M | XXX | $56.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2190.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 13990.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 25400.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 30158.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6759.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGoodwill Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Goodwill Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Goodwill Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Goodwill Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Goodwill Pharma acquired XXX companies to date.
Last acquisition by Goodwill Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Goodwill Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Goodwill Pharma headquartered? | Goodwill Pharma is headquartered in Hungary. |
| Is Goodwill Pharma publicy listed? | Yes, Goodwill Pharma is a public company listed on BUD. |
| What is the stock symbol of Goodwill Pharma? | Goodwill Pharma trades under GOODWILLPHRM ticker. |
| When did Goodwill Pharma go public? | Goodwill Pharma went public in 2022. |
| Who are competitors of Goodwill Pharma? | Similar companies to Goodwill Pharma include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Goodwill Pharma? | Goodwill Pharma's current market cap is $56.7M |
| Is Goodwill Pharma profitable? | Yes, Goodwill Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
